The Star Casino share price just rocketed 13%! Here's why

Star Casino shares are charging higher today. But why?

| More on:
A person in the dark background of a casino gambling room places his hands either side of a large pile of casino chips.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Star Entertainment Group Ltd (ASX: SGR) stockholders are enjoying a welcome day of outsized gains today.

The Star Casino share price closed yesterday at 11.5 cents. In earlier trade, shares in the S&P/ASX 200 Index (ASX: XJO) casino operator just leapt to 13.0 cents, up 13.0%. After some likely profit-taking, shares are changing hands for 12.25 cents apiece at the time of writing, up 6.5%.

For some context, the ASX 200 is up 0.6% at this same time.

Here's what's piquing investor interest on Wednesday.

Star Casino share price lifts on divestment

ASX 200 investors are bidding up the Star Casino share price after the embattled company announced a major divestment.

The company reported that its wholly owned subsidiary, Star Entertainment Sydney Properties, has executed an exclusivity arrangement and binding term sheet to divest The Star Sydney Event Centre and other spaces within The Star Sydney complex to Foundation Theatres.

The price tag for the assets is around $60 million, money sorely needed to keep the cash-strapped company afloat. Management noted that the transaction remains subject to a number of customary conditions, including relevant government and regulatory consent, as well as the finalisation of long-form transaction documents.

Commenting on the divestment that's lifting the Star Casino share price today, CEO Steve McCann said, "The Star has worked closely with the team at Foundation Theatres since they acquired the sublease for the Sydney Lyric in 2011."

McCann added:

We are pleased to partner with them as part of the continued evolution of our broad entertainment offerings at The Star Sydney. We continue to work on a number of other potential non-core asset transactions.

What's the latest from the ASX 200 casino operator?

After a horror year in 2024, 2025 hasn't given stockholders much to cheer about yet.

Last Monday, 20 January, the Star Casino share price crashed 17.9% on the heels of the company's second-quarter update.

Investors were favouring their sell buttons after the company reported a 15% quarter on quarter drop in revenue to $299 million.

Earnings before interest, taxes, depreciation and amortisation (EBITDA) improved over the quarter but still came in at a loss of $8 million (excluding significant items). That was up from an EBITDA loss of $18 million in the prior quarter.

Noting the company's reduction in available cash to $78 million at the end of the quarter, management warned that with "ongoing financial and liquidity challenges", Star was continuing to explore other possible liquidity solutions.

"In the absence of one or more of those arrangements, there remains material uncertainty as to the group's ability to continue as a going concern," management warned.

Despite today's boost, the Star Casino share price is still down a painful 76% from this time last year.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Consumer Staples & Discretionary Shares

Beef cattle in stockyard.
Consumer Staples & Discretionary Shares

Queensland floods to have a 'material' impact on this ASX agricultural stock's earnings

This company is likely to experience a material hit to earnings as a result of the floods in Queensland.

Read more »

A wine technician in overalls holds a glass of red wine up to the light and studies it.
Consumer Staples & Discretionary Shares

Treasury Wine shares keep the good times flowing

Brokers warn that the current lift is likely to be fragile.

Read more »

A man pushes a supermarket trolley with phone in hand down a supermarket aisle looking at the products on the shelves.
Consumer Staples & Discretionary Shares

Are Coles or Woolworths shares a better buy in 2026?

Which supermarket giant is the better buy this year?

Read more »

Young fruit picker clipping bunch of grapes in vineyard.
Consumer Staples & Discretionary Shares

Down over 50%, is this the ASX 200's greatest recovery share for 2026?

After a brutal year, Treasury Wine shares have been deeply sold off. Is a recovery starting to take shape for…

Read more »

A car dealer stands amid a selection of cars parked in a showroom.
Consumer Staples & Discretionary Shares

This ASX All Ords stock edges lower as investors digest key milestone

After completing a major acquisition, this ASX All Ords stock is back in focus as investors assess the next phase.

Read more »

A little boy surrounded by green grass and trees looks up at the sky, waiting for rain or sunshine.
Consumer Staples & Discretionary Shares

Why is Cobram Estate rocketing 17% today?

Cobram Estate shares jump 17% today after a broker upgrade and renewed confidence in its US growth plans.

Read more »

A young farnmer raise his arms to the sky as he stands in a lush field of wheat or farmland.
Consumer Staples & Discretionary Shares

These agricultural stocks are fundamentally undervalued, Bell Potter says

Bell Potter has named three stocks in the agricultural sector that it believes to be fundamentally undervalued.

Read more »

A baby's eyes open wide in surprise as it sucks on a milk bottle.
Consumer Staples & Discretionary Shares

Why this ASX small-cap share is back in focus after a US market update

A fresh US update has put Bubs shares back on investors’ radars as FDA approval moves closer and sales continue.

Read more »